<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02541773</url>
  </required_header>
  <id_info>
    <org_study_id>version 10 20 Jan 2016</org_study_id>
    <nct_id>NCT02541773</nct_id>
  </id_info>
  <brief_title>Novel Vascular Biomarkers Behaviour and Clinical Value in Heart Failure and CRT</brief_title>
  <acronym>COVERT-HF</acronym>
  <official_title>The Characterisation of Vascular Biomarkers Before and After Cardiac Resynchronization Therapy in Patients With Chronic Heart Failure and Their Role in Predicting Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Coventry and Warwickshire NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Coventry and Warwickshire NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand the behaviour of certain blood markers in patients&#xD;
      with heart failure who undergo a cardiac device implantation procedure called cardiac&#xD;
      resynchronization therapy (CRT). CRT is an effective treatment for heart failure, but up to&#xD;
      30% of people do not respond and have poor outcomes (1,2). Despite extensive investigation,&#xD;
      identifying these patients continues to be a challenge. The study intends to describe the&#xD;
      changes in these blood markers before and after CRT and to examine any potential clinical&#xD;
      value.&#xD;
&#xD;
      The idea behind the study is that these blood markers alter in heart failure and change with&#xD;
      CRT implantation. Furthermore the pattern of marker expression before implant and after may&#xD;
      predict response and outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design A prospective, non-randomised, self-control study of unselected heart failure&#xD;
      patients undergoing CRT implantation, all recruited within two years All participants having&#xD;
      CRT implantation at University Hospital Coventry and Warwickshire will be screened using the&#xD;
      eligibility criteria (outlined below).&#xD;
&#xD;
      Participants will have three assessments within six months (baseline, 6 weeks and 6 months&#xD;
      approximately). All visits coincide with routine clinical visits for CRT implantation and&#xD;
      interrogation. Assessments at all three time points will include clinical data (including New&#xD;
      York Heart Association functional class), quality of life measurements (Minnesota Living with&#xD;
      Heart Failure questionnaire), echocardiography data (left ventricular volumetric assessment,&#xD;
      ejection fraction), electrocardiograph, functional capacity (6 minute-walk test) and body&#xD;
      composition assessment (air displacement). Peripheral blood samples will be taken to examine&#xD;
      novel vascular biomarkers and to examine renal function, full blood count, diabetic control&#xD;
      (HBA1c - only diabetics) and Brain Natruetic Peptide. Coronary sinus samples will be taken&#xD;
      for novel vascular biomarkers in a small proportion of the cohort.&#xD;
&#xD;
      Blood Sampling and Storage&#xD;
&#xD;
      Participants are asked to starve for two hours and rest for one hour before blood sampling.&#xD;
      Coronary sinus blood sampling occurs at the time of coronary sinus cannulation before&#xD;
      contrast is injected. Blood samples (serum/plasma) are taken in citrate and EDTA tubes. The&#xD;
      samples stand at room temperature for a minimum of 30 minutes and undergo centrifugation&#xD;
      within an hour. Centrifugation (3500rpm for 10 minutes) occurs at room temperature. Samples&#xD;
      are then stored in -80 freezer.&#xD;
&#xD;
      Laboratory Analysis&#xD;
&#xD;
      Samples will undergo final analysis at the University of Warwick and Kings College London.&#xD;
      Novel vascular biomarkers of heart failure that exist as proteins in the serum will be&#xD;
      analysed using enzyme-linked immunosorbent assay (ELISA) techniques previously outlined in&#xD;
      publications (3-6). The specific novel vascular biomarkers represent different aspects of&#xD;
      adverse ventricular remodelling; myocardial stress [Growth Differentiation Factor-15] and&#xD;
      extracellular remodelling [Matrix Metalloproteinases -2 &amp; -9, Aminoterminal Propeptides of&#xD;
      Type I Collagen (PINP), Aminoterminal Propeptides of Type III Collagen (PIIINP),&#xD;
      Carboxy-Terminal Telopeptide of Type I Collagen (CITP)] (4-7). These markers will undergo&#xD;
      quantification using ELISA techniques that have previously described in the literature (8,&#xD;
      9).&#xD;
&#xD;
      Micro Ribonucleic Acids (miRNA) profiling will be undertaken in coronary sinus and peripheral&#xD;
      samples and will be compared to those taken after CRT implantation. Responders will be&#xD;
      compared to non-responders to determine variation in profile between these two distinct&#xD;
      groups. Profiling and quantification will be performed as described in previous publications&#xD;
      (10-12). Specific cardiac miRNA will be pre-selected to screen and quantify, especially those&#xD;
      have already been proven to have altered expression in heart failure (13-16).&#xD;
&#xD;
      Device Implantation&#xD;
&#xD;
      CRT devices (pacemaker of defibrillator) are implanted by two independent operators at our&#xD;
      single centre in a standard fashion. CRT is implanted traditionally in the left deltopectoral&#xD;
      groove. Venous access is via the cephalic&gt;axillary&gt;subclavian veins (all operators can&#xD;
      cannulate either vein based on individual patient). Right ventricular lead for the majority&#xD;
      of patients will be implanted at the right ventricular apex. Right atrial leads will be&#xD;
      planned to be implanted in the right atrial appendage. Patients in permanent Atrial&#xD;
      Fibrillation will not have a right atrial lead implanted. Coronary sinus will be cannulated&#xD;
      and angiography performed to roadmap anatomy for lead deployment site. The most lateral&#xD;
      position will be favoured in a basal/ mid-cavity position. At the point of coronary sinus&#xD;
      cannulation blood samples (plasma/serum will be taken). Post procedure patients undergo&#xD;
      targeted echocardiography and a chest x-ray film. Post procedure on the day of implant&#xD;
      patients will undergo CRT interrogation and optimisation of programming.&#xD;
&#xD;
      Echocardiography&#xD;
&#xD;
      A focused echocardiographic study assessing the left ventricle will be performed to the&#xD;
      recommended international standard (17). The left ventricular systolic and diastolic function&#xD;
      will be fully assessed. Volumetric assessment will be performed using Simpson's method (17).&#xD;
      Diastolic function will be assessed by performing volumetric assessment of the left atrium,&#xD;
      measuring pulse wave inflow of ventricular filling and TDI of the lateral and septal walls&#xD;
      [apical 4 chamber]. All scans will be performed on the departmental machines [GE systems,&#xD;
      Vivid 7] and by the same operator. Scans will be performed independently and previous scans&#xD;
      will not have been reviewed before this scan. Full analysis will be conducted once all scans&#xD;
      have been performed.&#xD;
&#xD;
      Inter- and Intra-Observer Variability Echocardiography Study&#xD;
&#xD;
      An inter- and intra-observer variability study will be performed to ensure standardisation of&#xD;
      echocardiographic examinations. Twenty percent of echocardiograms will be randomly selected&#xD;
      to have measurements and conclusions reviewed. An independent cardiologist/ cardiac&#xD;
      physiologist (accredited by the British Society of Echocardiography) will be blinded to&#xD;
      selected echocardiograms and will validate reporting and measurements of these examinations.&#xD;
&#xD;
      Body Composition&#xD;
&#xD;
      Air-displacement plethysmography (Bodpod) is an easily accessible and safe tool to measure&#xD;
      body composition (18). The assessment is reproducible and is comparable to other measures of&#xD;
      body composition (18). The major advantage of Bodpod is that it is safe for patients who have&#xD;
      had a CRT implanted. The University of Warwick and University Hospital Coventry and&#xD;
      Warwickshire (UHCW) has one of the few facilities in their Human Metabolic Unit to perform&#xD;
      Bodpod.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>6 months</time_frame>
    <description>Two of three criteria must be fulfilled to be defined as a clinical response:&#xD;
New York Heart Association (NYHA) &gt; 1 class reduction from baseline&#xD;
Minnesota Living with Heart Failure Questionnaire (MLHFQ) score &lt; 5 from baseline&#xD;
Six minute walk test (6MWT) increase in baseline distance by 10%&#xD;
Mortality or heart transplantation within 6 months of implant will be defined as a non-response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiovascular Outcomes</measure>
    <time_frame>12 months</time_frame>
    <description>Composite score of all-cause mortality and first heart failure hospitalisation (admission requiring intravenous diuretics)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic Response</measure>
    <time_frame>6 months</time_frame>
    <description>≥15% reduction in left ventricular end-systolic volume</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Chronic Heart Failure Patients</arm_group_label>
    <description>Undergoing CRT implantation, all will be observed for 6 months and will be defined at the end of the observation period as responder or non-responder</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac Resynchronisation Therapy</intervention_name>
    <description>Routine implantation of CRT - part of standard of care</description>
    <arm_group_label>Chronic Heart Failure Patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Participants with have peripheral and coronary sinus samples taken for plasma and serum.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic heart failure patients who have been referred for and meet national criteria for&#xD;
        Cardiac Resynchronization Therapy implants&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years&#xD;
&#xD;
          2. Left ventricular ejection fraction ≤35% on echocardiography&#xD;
&#xD;
          3. NYHA Class III/IV symptoms or milder symptoms with:&#xD;
&#xD;
               -  NYHA I (LVEF &lt;35% and QRS&gt;150msec on resting ECG)&#xD;
&#xD;
               -  NYHA II (LVEF &lt;35% with either QRS&gt;150msec or QRS 120-149msec with Left Bundle&#xD;
                  Branch Block on resting ECG)&#xD;
&#xD;
          4. Optimal medical therapy for heart failure that the patient tolerates (ACEi,&#xD;
             Beta-Blocker, Mineralocorticoid) for &gt; 3 months&#xD;
&#xD;
          5. QRS duration ≥120-149msec with LBBB on resting ECG or QRS duration &gt;150msec on resting&#xD;
             ECG&#xD;
&#xD;
          6. Patient consent to participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute heart failure decompensation &lt; 6/52 before implant&#xD;
&#xD;
          2. Significant cognitive impairment&#xD;
&#xD;
          3. Acute coronary syndrome &lt; 6/52 before implant&#xD;
&#xD;
          4. Chronic kidney disease stage V (requiring dialysis)&#xD;
&#xD;
          5. Terminal illness with likely survival &lt; 1 year after implant&#xD;
&#xD;
        Post Procedure Exclusions:&#xD;
&#xD;
        1. Failure of procedure (e.g. coronary sinus anatomy) 2. Complication resulting in poor/&#xD;
        none biventricular pacing (e.g. phrenic nerve stimulation, lead displacement/ damage)&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faizel Osman, MD FRCP FESC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Coventry and Warwickshire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Coventry and Warwickshire</name>
      <address>
        <city>Coventry</city>
        <state>Warwickshire</state>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005 Apr 14;352(15):1539-49. Epub 2005 Mar 7.</citation>
    <PMID>15753115</PMID>
  </reference>
  <reference>
    <citation>Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004 May 20;350(21):2140-50.</citation>
    <PMID>15152059</PMID>
  </reference>
  <reference>
    <citation>García-Bolao I, Macías A, López B, González A, Gavira JJ, Azcárate P, Alegría E, Díez J. A biomarker of myocardial fibrosis predicts long-term response to cardiac resynchronization therapy. J Am Coll Cardiol. 2006 Jun 6;47(11):2335-7. Epub 2006 May 16.</citation>
    <PMID>16750706</PMID>
  </reference>
  <reference>
    <citation>García-Bolao I, López B, Macías A, Gavira JJ, Azcárate P, Díez J. Impact of collagen type I turnover on the long-term response to cardiac resynchronization therapy. Eur Heart J. 2008 Apr;29(7):898-906. doi: 10.1093/eurheartj/ehn098. Epub 2008 Mar 10.</citation>
    <PMID>18334474</PMID>
  </reference>
  <reference>
    <citation>Hessel MH, Bleeker GB, Bax JJ, Henneman MM, den Adel B, Klok M, Schalij MJ, Atsma DE, van der Laarse A. Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels. Eur J Heart Fail. 2007 Oct;9(10):1058-63. Epub 2007 Aug 28.</citation>
    <PMID>17728181</PMID>
  </reference>
  <reference>
    <citation>Umar S, Bax JJ, Klok M, van Bommel RJ, Hessel MH, den Adel B, Bleeker GB, Henneman MM, Atsma DE, van der Wall EE, Schalij MJ, van der Laarse A. Myocardial collagen metabolism in failing hearts before and during cardiac resynchronization therapy. Eur J Heart Fail. 2008 Sep;10(9):878-83. doi: 10.1016/j.ejheart.2008.06.019. Epub 2008 Sep 2.</citation>
    <PMID>18768351</PMID>
  </reference>
  <reference>
    <citation>Foley PW, Stegemann B, Ng K, Ramachandran S, Proudler A, Frenneaux MP, Ng LL, Leyva F. Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. Eur Heart J. 2009 Nov;30(22):2749-57. doi: 10.1093/eurheartj/ehp300. Epub 2009 Aug 7.</citation>
    <PMID>19666898</PMID>
  </reference>
  <reference>
    <citation>Lewandowski KC, Komorowski J, Mikhalidis DP, Bienkiewicz M, Tan BK, O'Callaghan CJ, Lewinski A, Prelevic G, Randeva HS. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women. J Clin Endocrinol Metab. 2006 Aug;91(8):3123-30. Epub 2006 May 16.</citation>
    <PMID>16705077</PMID>
  </reference>
  <reference>
    <citation>Randeva HS, Lewandowski KC, Komorowski J, Murray RD, O'Callaghan CJ, Hillhouse EW, Stepien H, Shalet SM. Growth hormone replacement decreases plasma levels of matrix metalloproteinases (2 and 9) and vascular endothelial growth factor in growth hormone-deficient individuals. Circulation. 2004 May 25;109(20):2405-10. Epub 2004 May 3.</citation>
    <PMID>15123527</PMID>
  </reference>
  <reference>
    <citation>Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, Shah A, Willeit J, Mayr M. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010 Sep 17;107(6):810-7. doi: 10.1161/CIRCRESAHA.110.226357. Epub 2010 Jul 22.</citation>
    <PMID>20651284</PMID>
  </reference>
  <reference>
    <citation>Willeit P, Zampetaki A, Dudek K, Kaudewitz D, King A, Kirkby NS, Crosby-Nwaobi R, Prokopi M, Drozdov I, Langley SR, Sivaprasad S, Markus HS, Mitchell JA, Warner TD, Kiechl S, Mayr M. Circulating microRNAs as novel biomarkers for platelet activation. Circ Res. 2013 Feb 15;112(4):595-600. doi: 10.1161/CIRCRESAHA.111.300539. Epub 2013 Jan 2.</citation>
    <PMID>23283721</PMID>
  </reference>
  <reference>
    <citation>Zampetaki A, Mayr M. Analytical challenges and technical limitations in assessing circulating miRNAs. Thromb Haemost. 2012 Oct;108(4):592-8. Epub 2012 May 25.</citation>
    <PMID>22627831</PMID>
  </reference>
  <reference>
    <citation>Romaine SP, Tomaszewski M, Condorelli G, Samani NJ. MicroRNAs in cardiovascular disease: an introduction for clinicians. Heart. 2015 Jun;101(12):921-8. doi: 10.1136/heartjnl-2013-305402. Epub 2015 Mar 26. Review.</citation>
    <PMID>25814653</PMID>
  </reference>
  <reference>
    <citation>Marfella R, Di Filippo C, Potenza N, Sardu C, Rizzo MR, Siniscalchi M, Musacchio E, Barbieri M, Mauro C, Mosca N, Solimene F, Mottola MT, Russo A, Rossi F, Paolisso G, D'Amico M. Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders. Eur J Heart Fail. 2013 Nov;15(11):1277-88. doi: 10.1093/eurjhf/hft088. Epub 2013 Jun 4.</citation>
    <PMID>23736534</PMID>
  </reference>
  <reference>
    <citation>Vogel B, Keller A, Frese KS, Leidinger P, Sedaghat-Hamedani F, Kayvanpour E, Kloos W, Backe C, Thanaraj A, Brefort T, Beier M, Hardt S, Meese E, Katus HA, Meder B. Multivariate miRNA signatures as biomarkers for non-ischaemic systolic heart failure. Eur Heart J. 2013 Sep;34(36):2812-22. doi: 10.1093/eurheartj/eht256. Epub 2013 Jul 17.</citation>
    <PMID>23864135</PMID>
  </reference>
  <reference>
    <citation>Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, Pinto YM. MiR423-5p as a circulating biomarker for heart failure. Circ Res. 2010 Apr 2;106(6):1035-9. doi: 10.1161/CIRCRESAHA.110.218297. Epub 2010 Feb 25.</citation>
    <PMID>20185794</PMID>
  </reference>
  <reference>
    <citation>Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ; Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005 Dec;18(12):1440-63.</citation>
    <PMID>16376782</PMID>
  </reference>
  <reference>
    <citation>Fields DA, Goran MI, McCrory MA. Body-composition assessment via air-displacement plethysmography in adults and children: a review. Am J Clin Nutr. 2002 Mar;75(3):453-67. Review.</citation>
    <PMID>11864850</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>September 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <last_update_submitted>March 8, 2016</last_update_submitted>
  <last_update_submitted_qc>March 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Coventry and Warwickshire NHS Trust</investigator_affiliation>
    <investigator_full_name>Dr Christopher McAloon</investigator_full_name>
    <investigator_title>Cardiology Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Chronic Heart Failure</keyword>
  <keyword>Cardiac Resynchronization Therapy</keyword>
  <keyword>Vascular Biomarker</keyword>
  <keyword>miRNA</keyword>
  <keyword>Extracellular Matrix</keyword>
  <keyword>Brain Natruetic Peptide</keyword>
  <keyword>Growth Degradation Factor-15</keyword>
  <keyword>Body Composition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>September 26, 2019</submitted>
    <returned>October 18, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

